Poxel S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PXXLF research report →
About the company
Poxel S. A. , a biopharmaceutical firm in the clinical stage, is dedicated to creating innovative treatments for a range of metabolic disorders, including type 2 diabetes and various liver ailments.
- CEO
- Nicolas Trouche
- IPO
- 2017
- Employees
- 6
- HQ
- Lyon, FR
Price Chart
- Market Cap
- $15.97M
- P/E
- -0.54
- P/S
- 1.64
- P/B
- -0.16
- EV/EBITDA
- -17.80
- Div Yield
- 0.00%
- Gross Margin
- 55.12%
- Op Margin
- -55.18%
- Net Margin
- -275.84%
- ROE
- 33.88%
- ROIC
- -33.64%
- Revenue
- $6.63M · 234.89%
- Net Income
- $-18,299,727 · 47.85%
- EPS
- $-0.42 · 53.85%
- Op Income
- $-4,339,749
- FCF YoY
- 31.94%
- 52W High
- $0.70
- 52W Low
- $0.25
- 50D MA
- $0.26
- 200D MA
- $0.25
- Beta
- 1.28
- Avg Volume
- 65.732
Get TickerSpark's AI analysis on PXXLF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our PXXLF coverage
Recent articles, reports, and earnings notes.
No research on PXXLF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PXXLF report →Similar companies
Peers in the same neighborhood.